ArchiMed Group

Natus Medical (Nasdaq:NTUS) announced today that ArchiMed’s investment firm completed its previously announced acquisition of the company.

In April, the company announced that the MED Platform II fund of ArchiMed — an investment firm focused on the healthcare industry — would acquire Natus, a developer of medical devices for screening, diagnosing and treating disorders affecting the brain, neural pathways, and eight sensory nervous systems, for a total equity value of $1.2 billion.

Under the terms of the acquisition, Natus shareholders received $33.50 in cash for each share of common stock, according to a news release.

“ArchiMed’s mix of operational, medical, scientific and financial expertise will help us continue our mission to serve our customers as we internationalize and grow our business,” Natus CEO Thomas J. Sullivan said in the release. “Our Natus teammates are excited to advance the standard of care and improve outcomes and quality o…

Natus Medical today announced that it entered a definitive agreement to be acquired by Archimed for a total equity value of $1.2 billion.

Through the agreement, Natus shareholders will receive $33.50 in cash for each share of Natus common stock to represent a 29% premium to the stock’s close price on April 14.

“The sale of Natus Medical to ArchiMed will provide our shareholders with immediate and substantial cash value, as well as a compelling premium, and the Board has unanimously agreed that this transaction is in the best interests of our shareholders,” Natus Medical Chairperson Joshua Levine said in an SEC filing.

Natus shareholders will receive $33.50 in cash for each share of the company’s common stock they own. The transaction is expected to close in the third quarter of 2022 and is subject to customary closing conditions and approval by Natus shareholders and regulatory approvals. According to the company, once the acquisition is comp…